
News
- Home
- >
- News
Latest news
-
19 October 2022SERB Presents Preclinical Data Showing Initial Efficacy of COVID-19 Treatment Developed with Polyclonal Antibody PlatformWashington D.C., 19 October 2022: SERB Pharmaceuticals today announces preclinical data demonstrating initial efficacy of a new polyclonal, ovine fragment antibody (Fab) developed as a treatment for COVID-19. The data will be presented as a poster at IDWeek 2022, the annual meeting of the Infectious Diseases Society of America, held in Washington DC on October […]
-
04 August 2022SERB Pharmaceuticals licenses Soligenix Antigen to Develop Ricin AntidoteSERB Pharmaceuticals has signed a worldwide exclusive license to use an antigen from Soligenix [NSDQ: SNGX] to develop a novel therapeutic treatment for ricin poisoning. There is an unmet need for protection against this highly potent toxin for which there is no vaccine or therapeutic intervention available. To develop the ricin antidote, SERB will leverage its unique […]
-
09 June 2022Four Independent Studies of Voraxaze® Published at European Hematology Conference 2022Vienna – 9 June 2022 – The European Hematology Association (EHA) Conference published four independent studies of Voraxaze® (glucarpidase) by various investigators for inclusion in its June 2022 EHA Hybrid Congress abstract book and for publication in HemaSphere, EHA’s peer-reviewed, open access journal. All four abstracts are the result of independent studies in Europe and […]
News archive
Date
Title